{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:44:03Z","timestamp":1791233043477,"version":"4.1.0"},"reference-count":107,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatopathology"],"abstract":"<jats:p>Despite therapeutic advancements, malignant melanoma remains a leading cause of skin cancer-related mortality, with incidence continuing to rise globally. Traditional prognostic tools offer important clinical guidance but fail to capture the biological heterogeneity of melanoma or reliably predict responses to emerging therapies. In this review, we summarize recent advances in prognostic and predictive molecular biomarkers reported over the past five years. We discuss immunohistochemical and tissue-based markers, circulating biomarkers, microRNAs, and gene expression profiles that enhance risk stratification and inform surveillance strategies. We also review immune-related markers that may predict response to immune-checkpoint inhibitor therapy. Lastly, we highlight investigational biomarkers\u2014including gene signatures, epigenomic alterations, and microbiome influences\u2014that are shaping the future landscape. Together, these advances reflect a shift toward precision oncology in melanoma, with the integration of biomarker-driven strategies offering the potential to personalize treatment and improve patient outcomes.<\/jats:p>","DOI":"10.3390\/dermatopathology12030031","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T13:43:02Z","timestamp":1757684582000},"page":"31","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Molecular and Genetic Markers for Malignant Melanoma: Implications for Prognosis and Therapy"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8534-6999","authenticated-orcid":false,"given":"Lauren","family":"Fleshner","sequence":"first","affiliation":[{"name":"School of Medicine, New York Medical College, Valhalla, NY 10595, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9392-6615","authenticated-orcid":false,"given":"Alyssa","family":"Sayegh","sequence":"additional","affiliation":[{"name":"School of Medicine, New York Medical College, Valhalla, NY 10595, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1751-3000","authenticated-orcid":false,"given":"Mehmet Fatih","family":"Atak","sequence":"additional","affiliation":[{"name":"School of Medicine, New York Medical College, Valhalla, NY 10595, USA"},{"name":"Dermatology Department, NYC Health + Hospital\/Metropolitan, New York, NY 10029, USA"},{"name":"Dermatology Department, NYC Health + Hospital\/South Brooklyn Health, Brooklyn, NY 11235, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9304-9916","authenticated-orcid":false,"given":"Rahim","family":"Hirani","sequence":"additional","affiliation":[{"name":"School of Medicine, New York Medical College, Valhalla, NY 10595, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4748-1556","authenticated-orcid":false,"given":"Banu","family":"Farabi","sequence":"additional","affiliation":[{"name":"School of Medicine, New York Medical College, Valhalla, NY 10595, USA"},{"name":"Dermatology Department, NYC Health + Hospital\/Metropolitan, New York, NY 10029, USA"},{"name":"Dermatology Department, NYC Health + Hospital\/South Brooklyn Health, Brooklyn, NY 11235, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijan","family":"Safai","sequence":"additional","affiliation":[{"name":"School of Medicine, New York Medical College, Valhalla, NY 10595, USA"},{"name":"Dermatology Department, NYC Health + Hospital\/Metropolitan, New York, NY 10029, USA"},{"name":"Dermatology Department, NYC Health + Hospital\/South Brooklyn Health, Brooklyn, NY 11235, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8489-961X","authenticated-orcid":false,"given":"Shoshana","family":"Marmon","sequence":"additional","affiliation":[{"name":"School of Medicine, New York Medical College, Valhalla, NY 10595, USA"},{"name":"Dermatology Department, NYC Health + Hospital\/South Brooklyn Health, Brooklyn, NY 11235, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/DAD.0b013e31828a2ec5","article-title":"Cutaneous Malignant Melanoma: Update on Diagnostic and Prognostic Biomarkers","volume":"36","author":"Abbas","year":"2014","journal-title":"Am. J. Dermatopathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e2245269","DOI":"10.1001\/jamanetworkopen.2022.45269","article-title":"Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019","volume":"5","author":"Kahlon","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","article-title":"Cancer immunotherapy: It\u2019s time to better predict patients\u2019 response","volume":"125","author":"Pilard","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: Implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","article-title":"NCCN Guidelines\u00ae Insights: Melanoma: Cutaneous, Version 2.2024","volume":"22","author":"Swetter","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40257-017-0325-6","article-title":"Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives","volume":"19","author":"Rozeman","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_8","first-page":"44","article-title":"Prognostic Biomarkers in Melanoma: Tailoring Treatments to the Patient","volume":"14","author":"Safai","year":"2021","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME Expression in Melanocytic Tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/DAD.0000000000002863","article-title":"The Utility of PRAME and Ki-67 as Prognostic Markers for Cutaneous Melanoma","volume":"47","author":"Asato","year":"2025","journal-title":"Am. J. Dermatopathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"154543","DOI":"10.1016\/j.prp.2023.154543","article-title":"Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases","volume":"247","author":"Broggi","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/PAS.0000000000001393","article-title":"Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma","volume":"44","author":"Lezcano","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cassalia, F., Danese, A., Tudurachi, I., Federico, S., Zambello, A., Guidotti, A., Franceschin, L., Bolzon, A., Naldi, L., and Fortina, A.B. (2024). PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031582"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Liu, Q., Peng, Z., Shen, L., and Shen, L. (2021). Prognostic and Clinicopathological Value of Ki-67 in Melanoma: A Meta-Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.737760"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13077","DOI":"10.1007\/s00432-023-05127-w","article-title":"A nomogram incorporating Ki67 to predict survival of acral melanoma","volume":"149","author":"Du","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/bjd\/ljad459","article-title":"Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for nonulcerated American Joint Committee on Cancer stage I\/II cutaneous melanoma","volume":"190","author":"Ewen","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1541-7786.MCR-17-0528","article-title":"YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMT","volume":"16","author":"Kosnopfel","year":"2018","journal-title":"Mol. Cancer Res. MCR"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.molmed.2006.07.008","article-title":"MITF: Master regulator of melanocyte development and melanoma oncogene","volume":"12","author":"Levy","year":"2006","journal-title":"Trends Mol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/jid.2014.319","article-title":"Pro-Survival Role of MITF in Melanoma","volume":"135","author":"Hartman","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1600-0560.2006.00501.x","article-title":"Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma","volume":"33","author":"Hammock","year":"2006","journal-title":"J. Cutan. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jaad.2004.08.034","article-title":"Molecular diagnostics in melanoma","volume":"52","author":"Carlson","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","first-page":"472","article-title":"Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ijc.27991","article-title":"Clinical use of p-proteasome in discriminating metastatic melanoma patients: Comparative study with LDH, MIA and S100B protein","volume":"133","author":"Henry","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bjc.2015.467","article-title":"Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma","volume":"114","author":"Diem","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e25318","DOI":"10.1097\/MD.0000000000025318","article-title":"Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1\/PD-L1 therapy","volume":"100","author":"Xu","year":"2021","journal-title":"Medicine"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Prka\u010din, I., Mokos, M., Ferara, N., and \u0160itum, M. (2024). Melanoma\u2019s New Frontier: Exploring the Latest Advances in Blood-Based Biomarkers for Melanoma. Cancers, 16.","DOI":"10.3390\/cancers16244219"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Janka, E.A., V\u00e1rv\u00f6lgyi, T., Sipos, Z., So\u00f3s, A., Hegyi, P., Kiss, S., Dembrovszky, F., Csupor, D., K\u00e9ringer, P., and P\u00e9csi, D. (2021). Predictive Performance of Serum S100B Versus LDH in Melanoma Patients: A Systematic Review and Meta-Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.772165"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41416-018-0167-x","article-title":"S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies","volume":"119","author":"Wagner","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Revythis, A., Shah, S., Kutka, M., Moschetta, M., Ozturk, M.A., Pappas-Gogos, G., Ioannidou, E., Sheriff, M., Rassy, E., and Boussios, S. (2021). Unraveling the Wide Spectrum of Melanoma Biomarkers. Diagnostics, 11.","DOI":"10.3390\/diagnostics11081341"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cca.2013.11.034","article-title":"Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients","volume":"429","author":"Sanmamed","year":"2014","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1186\/s12967-024-05783-7","article-title":"Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment","volume":"22","author":"Marchisio","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Dao, J., Conway, P.J., Subramani, B., Meyyappan, D., Russell, S., and Mahadevan, D. (2023). Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713219"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CMR.0000000000001041","article-title":"Circulating tumor DNA predicts tumor progression and poor survival in patients with stage III melanoma","volume":"35","author":"Boada","year":"2025","journal-title":"Melanoma Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Knuever, J., Weiss, J., Persa, O.-D., Kreuzer, K., Mauch, C., Hallek, M., and Schlaak, M. (2020). The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-61818-1"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/jdv.16766","article-title":"The predictive and prognostic significance of cell-free DNA concentration in melanoma","volume":"35","author":"Elouali","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jmoldx.2023.06.014","article-title":"Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma","volume":"25","author":"Aoude","year":"2023","journal-title":"J. Mol. Diagn."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.34716","article-title":"Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients","volume":"129","author":"Eroglu","year":"2023","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e1090","DOI":"10.1002\/ctm2.1090","article-title":"Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype","volume":"12","author":"Albrecht","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Prodan, M., Dema, A., Nataras, B.R., Seclaman, E., Bloanca, V., Crainiceanu, Z., Deak, I.E., Virzob, C.R.B., Toma, A.-O., and Fericean, R.M. (2024). Prognostic Significance of miRNA Subtypes in Melanoma: A Survival Analysis and Correlation with Treatment Response Across Patient Stages. Biomedicines, 12.","DOI":"10.3390\/biomedicines12122809"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.7754\/Clin.Lab.2019.190917","article-title":"MiR-424 Functions as Potential Diagnostic and Prognostic Biomarker in Melanoma","volume":"66","author":"Xu","year":"2020","journal-title":"Clin. Lab."},{"key":"ref_41","first-page":"38","article-title":"Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma","volume":"125","author":"Amaral","year":"2020","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"key":"ref_42","first-page":"11","article-title":"Identification of stage I\/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model","volume":"140","author":"Eggermont","year":"2020","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"103288","DOI":"10.1016\/j.critrevonc.2021.103288","article-title":"TERT promoter mutations and melanoma survival: A comprehensive literature review and meta-analysis","volume":"160","author":"Gandini","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ning, B., Liu, Y., Wang, M., Li, Y., Xu, T., and Wei, Y. (2022). The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.748674"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e2300640","DOI":"10.1200\/PO.23.00640","article-title":"Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma","volume":"8","author":"Andrews","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Castellani, G., Buccarelli, M., Arasi, M.B., Rossi, S., Pisanu, M.E., Bellenghi, M., Lintas, C., and Tabolacci, C. (2023). BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers. Cancers, 15.","DOI":"10.3390\/cancers15164026"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/0284186X.2020.1747636","article-title":"BRAF mutational status as a prognostic marker for survival in malignant melanoma: A systematic review and meta-analysis","volume":"59","author":"Ny","year":"2020","journal-title":"Acta Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Heppt, M.V., Siepmann, T., Engel, J., Schubert-Fritschle, G., Eckel, R., Mirlach, L., Kirchner, T., Jung, A., Gesierich, A., and Ruzicka, T. (2017). Prognostic significance of BRAF and NRAS mutations in melanoma: A German study from routine care. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3529-5"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2023.04.008","article-title":"Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: A multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG","volume":"188","author":"Zaremba","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Danishevich, A., Bilyalov, A., Nikolaev, S., Khalikov, N., Isaeva, D., Levina, Y., Makarova, M., Nemtsova, M., Chernevskiy, D., and Sagaydak, O. (2023). CDKN2A Gene Mutations: Implications for Hereditary Cancer Syndromes. Biomedicines, 11.","DOI":"10.3390\/biomedicines11123343"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9","article-title":"CDKN2A (p16INK4A) somatic and germline mutations","volume":"7","author":"Hovig","year":"1996","journal-title":"Hum. Mutat."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2021.10.024","article-title":"Lack of association between CDKN2A germline mutations and survival in patients with melanoma: A retrospective cohort study","volume":"87","author":"Ipenburg","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/jdv.18796","article-title":"Surveillance, CDKN2A and survival of familial melanoma","volume":"37","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Lin, Z., and Yang, L. (2024). Identification of a CpG-based signature coupled with gene expression as prognostic indicators for melanoma: A preliminary study. Sci. Rep., 14.","DOI":"10.1038\/s41598-023-50614-2"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2487316","DOI":"10.1080\/15592294.2025.2487316","article-title":"A qualitative prognostic biomarker for melanoma based on the relative methylation orderings of CpG loci","volume":"20","author":"Huo","year":"2025","journal-title":"Epigenetics"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Meevassana, J., Varophas, S., Prabsattru, P., Kamolratanakul, S., Ruangritchankul, K., and Kitkumthorn, N. (2024). 5-Methylcytosine immunohistochemistry for predicting cutaneous melanoma prognosis. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-58011-z"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e18109","DOI":"10.1111\/jcmm.18109","article-title":"Long non-coding RNA as a potential diagnostic and prognostic biomarker in melanoma: A systematic review and meta-analysis","volume":"28","author":"Masrour","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Guo, S., Chen, J., Yi, X., Lu, Z., and Guo, W. (2022). Identification and validation of ferroptosis-related lncRNA signature as a prognostic model for skin cutaneous melanoma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.985051"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Zhou, J.-G., Liang, B., Liu, J.-G., Jin, S.-H., He, S.-S., Frey, B., Gu, N., Fietkau, R., Hecht, M., and Ma, H. (2021). Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy. Cells, 10.","DOI":"10.3390\/cells10050977"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Sorroche, B.P., Teixeira, R.d.J., Pereira, C.A.D., Santana, I.V.V., Vujanovic, L., Vazquez, V.d.L., and Arantes, L.M.R.B. (2023). PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors\u2019 Response and Survival in Advanced Melanoma Patients in Brazil. Diagnostics, 13.","DOI":"10.3390\/diagnostics13061041"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"113476","DOI":"10.1016\/j.ejca.2023.113476","article-title":"PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma","volume":"198","author":"Ellebaek","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40257-024-00910-y","article-title":"Prognostic Biomarkers in Evolving Melanoma Immunotherapy","volume":"26","author":"Reschke","year":"2025","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2261248","DOI":"10.1080\/2162402X.2023.2261248","article-title":"Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies","volume":"12","author":"Gide","year":"2023","journal-title":"Oncoimmunology"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Arimura, K., Hiroshima, K., Nagashima, Y., Nakazawa, T., Ogihara, A., Orimo, M., Sato, Y., Katsura, H., Kanzaki, M., and Kondo, M. (2023). LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: A retrospective study. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11636-1"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1926762","DOI":"10.1080\/2162402X.2021.1926762","article-title":"Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients","volume":"10","author":"Machiraju","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2430066","DOI":"10.1080\/2162402X.2024.2430066","article-title":"The immune checkpoint LAG-3 is expressed by melanoma cells and correlates with clinical progression of the melanoma","volume":"14","author":"Wiecken","year":"2025","journal-title":"Oncoimmunology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e00808","DOI":"10.1002\/prp2.808","article-title":"Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers","volume":"9","author":"Navani","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Ferreira, A.M.C., Carron, J., Gomez, G.V.B., Vazquez, V.L., Serrano, S.V., Louren\u00e7o, G.J., and Lima, C.S.P. (2024). Association of Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) Genetic Variants with Risk and Outcome of Cutaneous Melanoma. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252212327"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"108428","DOI":"10.1016\/j.clim.2020.108428","article-title":"Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab","volume":"215","author":"Pistillo","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00262-020-02494-y","article-title":"Response to ipilimumab therapy in metastatic melanoma patients: Potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization","volume":"69","author":"Mastracci","year":"2020","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_72","first-page":"2061","article-title":"MC1R Common Variants and the 10-Year Survival after Melanoma in Polish Population","volume":"9","author":"Baszuk","year":"2024","journal-title":"Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e2300702","DOI":"10.1200\/PO.23.00702","article-title":"Melanocortin 1 receptor (MC1R) expression as a marker of progression in melanoma","volume":"8","author":"Su","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00412-018-0659-8","article-title":"Ki-67: More than a proliferation marker","volume":"127","author":"Sun","year":"2018","journal-title":"Chromosoma"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"DiVincenzo, M.J., Angell, C.D., Suarez-Kelly, L.P., Ren, C., Barricklow, Z., Moufawad, M., Fadda, P., Yu, L., Backes, F.J., and Ring, K. (2023). Expression of microRNAs and their target genes in melanomas originating from gynecologic sites. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0285804"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Cheng, Y., and Shen, P. (2020). miR-335 Acts as a Tumor Suppressor and Enhances Ionizing Radiation-Induced Tumor Regression by Targeting ROCK1. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00278"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.3390\/curroncol31050220","article-title":"Molecular Markers in Melanoma Progression: A Study on the Expression of miRNA Gene Subtypes in Tumoral vs. Benign Nevi","volume":"31","author":"Prodan","year":"2024","journal-title":"Curr. Oncol. (Tor. Ont.)"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2019.11.010","article-title":"MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma","volume":"97","author":"Nakahara","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"357","DOI":"10.32604\/or.2024.050878","article-title":"Melanoma cell line-derived exosomal miR-424-5p: A key promoter of angiogenesis through LATS2 interaction","volume":"33","author":"Du","year":"2025","journal-title":"Oncol. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-4939-3652-6_3","article-title":"Introduction to the Gene Expression Analysis","volume":"1434","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e2300044","DOI":"10.1200\/PO.23.00044","article-title":"31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration","volume":"7","author":"Bailey","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Sun, J., Karasaki, K.M., and Farma, J.M. (2024). The Use of Gene Expression Profiling and Biomarkers in Melanoma Diagnosis and Predicting Recurrence: Implications for Surveillance and Treatment. Cancers, 16.","DOI":"10.3390\/cancers16030583"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/bjd.19499","article-title":"Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma","volume":"184","author":"Mulder","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_84","first-page":"2350-A0019","article-title":"Telomerase gene promoter (TERT) mutation in recurrent uveal melanoma after secondary enucleation revealed by targeted next-generation sequencing","volume":"63","author":"Perzia","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: Clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Czarnecka, A.M., Bartnik, E., Fiedorowicz, M., and Rutkowski, P. (2020). Targeted Therapy in Melanoma and Mechanisms of Resistance. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134576"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaad.2013.10.064","article-title":"Prognostic value of BRAF mutations in localized cutaneous melanoma","volume":"70","author":"Nagore","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Rizzetto, G., De Simoni, E., Molinelli, E., Offidani, A., and Simonetti, O. (2023). Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202306.1811.v1"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/pcmr.12516","article-title":"Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors","volume":"29","author":"Guida","year":"2016","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMra2034861","article-title":"Recent Advances in the Treatment of Melanoma","volume":"384","author":"Curti","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1158\/1078-0432.CCR-21-2138","article-title":"Molecular Pathways and Mechanisms of BRAF in Cancer Therapy","volume":"28","author":"Poulikakos","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pathol.2023.11.004","article-title":"Prognostic and predictive biomarkers in melanoma","volume":"56","author":"Maher","year":"2024","journal-title":"Pathology"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Teixido, C., Castillo, P., Martinez-Vila, C., Arance, A., and Alos, L. (2021). Molecular Markers and Targets in Melanoma. Cells, 10.","DOI":"10.3390\/cells10092320"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Szab\u00f3, I.L., Emri, G., Lad\u00e1nyi, A., and T\u00edm\u00e1r, J. (2025). Clinical Applications of the Molecular Landscape of Melanoma: Integration of Research into Diagnostic and Therapeutic Strategies. Cancers, 17.","DOI":"10.3390\/cancers17091422"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Jia, D.-D., and Li, T. (2024). Comprehensive insights on genetic alterations and immunotherapy prognosis in Chinese melanoma patients. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-65065-6"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/jamadermatol.2023.0127","article-title":"Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing","volume":"159","author":"Leachman","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Tonella, L., Pala, V., Ponti, R., Rubatto, M., Gallo, G., Mastorino, L., Avallone, G., Merli, M., Agostini, A., and Fava, P. (2021). Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094561"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Puglisi, R., Bellenghi, M., Pontecorvi, G., Pallante, G., Car\u00e8, A., and Mattia, G. (2021). Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13122875"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/14737159.2024.2347484","article-title":"Prognostic biomarkers in melanoma: A 2023 update from clinical trials in different therapeutic scenarios","volume":"24","author":"Roccuzzo","year":"2024","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Hossain, S.M., Carpenter, C., and Eccles, M.R. (2024). Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future Perspectives. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25137252"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Adeuyan, O., Gordon, E.R., Kenchappa, D., Bracero, Y., Singh, A., Espinoza, G., Geskin, L.J., and Saenger, Y.M. (2023). An update on methods for detection of prognostic and predictive biomarkers in melanoma. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1290696"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"He, R., Lu, J., Feng, J., Lu, Z., Shen, K., Xu, K., Luo, H., Yang, G., Chi, H., and Huang, S. (2024). Advancing immunotherapy for melanoma: The critical role of single-cell analysis in identifying predictive biomarkers. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1435187"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"T\u00edm\u00e1r, J., and Lad\u00e1nyi, A. (2022). Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105384"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Svedman, F.C., Das, I., Tuominen, R., Ramqvist, E.D., H\u00f6iom, V., and Brage, S.E. (2022). Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma. Cancers, 14.","DOI":"10.3390\/cancers14153587"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Pilla, L., Alberti, A., Di Mauro, P., Gemelli, M., Cogliati, V., Cazzaniga, M.E., Bidoli, P., and Maccalli, C. (2020). Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects. Cancers, 12.","DOI":"10.3390\/cancers12113456"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Seyhan, A.A., and Carini, C. (2022). Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010041"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"He, Y., and Wang, X. (2023). Identifying biomarkers associated with immunotherapy response in melanoma by multi-omics analysis. Comput. Biol. Med., 167.","DOI":"10.1016\/j.compbiomed.2023.107591"}],"container-title":["Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2296-3529\/12\/3\/31\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:44:43Z","timestamp":1760035483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2296-3529\/12\/3\/31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":107,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["dermatopathology12030031"],"URL":"https:\/\/doi.org\/10.3390\/dermatopathology12030031","relation":{},"ISSN":["2296-3529"],"issn-type":[{"value":"2296-3529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]}}}